For cytostatic agents or when the response assessment is difficult, adaptations to phase II designs may allow a better assessment of therapeutic activity: first by using the progression-free survival rate (PFSR) as primary end-point instead of the response rate, and second by considering progression-free survival (PFS) risk groups based on a prognostic index (PI).
We began by using the very uniform mitotic progression of cells containing GFP-labelled tubulin to assign ET reconstructions to a specific time during mitosis.
Furthermore, by using the human MCF10A breast cancer progression model, we showed that increased FAK expression in metastatic breast cancer cells mirrored the acquisition of enhanced activation of p38 MAPK by TGF-β.
We illustrated this shift in TGF-β signaling by using the human MCF10A breast cancer progression model that consists of indolent (T1K), malignant nonmetastatic (Ca1h), and malignant metastatic (Ca1a) cells [ 26, 27].
For this reason, our study assessed the functional and structural progressions by using the event analysis of the GPA software for both the HFA and OCT.
Response and progression was determined by using the Response Evaluation Criteria in Solid Tumors (RECIST).
In particular, modellers could consider using alternative approaches to modelling the influence of SPVL on late-stage progression, for example, by using the results of our Cox proportional hazard analysis which suggest that, for individuals with CD4+ less than 200 cells/μl, the death hazard increases by 63% for each log10 increase in SPVL.
Once an exercise is no longer challenging for the participant they will be instructed to progress to the next level of difficulty by changing the exercise using the following progressions: closing eyes, reducing base of support, confounding visual fixation (e.g. head turns), changing centre of mass (e.g. arm/leg lifts) or adding a secondary manual or cognitive task.
Training intensity (loads) progression was ensured by using progressively more resistant elastic bands and heavier kettlebells throughout the 10-week intervention period, as supervised by the instructors.
Sieve PSDs are usually measured by using a systematic mathematical progression in sieve aperture size; therefore, the fractions from the 1.7- and 2.0-mm sieves were combined, as were those from the 0.85- and 1.0-mm sieves, so that aperture size roughly doubled at each step.
Colom et al. (2010) investigated whether treatment response is affected by course of illness progression using the Kaplan Meier survival analysis.
